Milstein gets Vice President role at Cardio3


Belgian biotechnology company, Cardio3 BioSciences, a developer of regenerative and protective therapies for the treatment of cardiac diseases, has appointed Dr Alexander Milstein to the position of Vice President of Clinical Development. Milstein will lead the clinical development programme for C3BS-CQR-1, which is due to enter Phase III later in 2012, as well as advancing the company's other products into clinical development. Prior to joining Cardio3, Milstein held the position of Vice President, Clinical Development at Cytori Therapeutics.

This article is tagged to:
Sector: Medical Devices
Geography: Belgium

Access all of our latest analysis, data and forecasts - request a trial